Social-economic burden of severe atopic dermatitis in the Russian Federation
Abstract
Atopic dermatitis (AD) is a chronic systemic disease with skin lesion, inflammation caused by mediators plays important role in its pathogenesis. Severe AD characterizes by permanent exacerbations that leads to sufferings and, influences on physical and emotional conditions and losses of patient’s productivity. Modern drugs including biologicals have a good clinical efficacy, but the same time AD burden (cost of illness) in the Russian conditions are not evaluated yet. Direct medical and nonmedical costs, non-direct costs in severe AD in adults based on prevalence data, statistics of finances covering of out-patients and in-patients treatment options, experts’ opinions, reports about temporary disability, losses of GDP etc. have been calculated. Burden of severe AD in local practice can be evaluated as 564 242 RUR/patient/year in working age and 263 230,5 RUR/patient/ year in aged population. Social-economic burden of severe AD in the Russian Federation can reach 13,074 Bln RUR annually (12,031 Bln RUR for working patients and 1,043 Bln RUR for aged population of patients). Direct non-medical and non-direct costs have at least 50 % of all expenditures that highlighting of social importance of severe AD.
About the Authors
I. S. Krysanov
Medical Institute of Continuing Education; Institute of clinical-economic expertise & pharmacoeconomics, JSC
Russian Federation
Russian Federation
Krysanov Inan – Candidate of Pharmaceutical Sciences, Assistant professor, Head of the Department of Pharmacy in Medical Institute of Continuing Education. SPIN code: 1290-4976
Moscow
V. S. Krysanova
Medical Institute of Continuing Education; First Moscow State Medical University named by Sechenov; Scientifi and Practical Center for Clinical and Economic Analysis of Ministry of Health of the Moscow Region
Russian Federation
Russian Federation
Krysanova Vera – MD, Researcher in SBI of MR «Scientific and Practical Center for Clinical and Economic Analysis of Ministry of Health of the Moscow Region»; Lecture of the Department of Therapy and Children’s Diseases in Medical Institute of Continuing Education, MSUFP; PhD student of Department of Clinical pharmacology and Propaedeutic of internal diseases in N.V. Sklifosovsky Institute of Clinical Medicine, Sechenov University. SPIN code: 6433-2420
Moscow
Krasnogorsk
O. I. Karpov
JSC Sanofi Russia
Russian Federation
Russian Federation
Karpov Oleg – MD, DrSci, Professor, Head of Eurasia HEOR
Moscow
V. Yu. Ermakova
Institute of clinical-economic expertise & pharmacoeconomics, JSC; First Moscow State Medical University named by Sechenov
Russian Federation
Russian Federation
Ermakova Viktoriya – Candidate of Pharmaceutical Sciences, Assistant professor of the Department of Pharmacy in A.P. Nelyubin Institute. SPIN code: 8039-3069
Moscow
References
1. Oliveira C, Torres T. More than skin deep: the systemic nature of atopic dermatitis. Eur Journal Dermatology. 2019;29(3):250-258. DOI:10.1684/ejd.2019.3557.
2. Federal’nye klinicheskie rekomendacii po vedeniyu bol’nyh atopicheskim dermatitom. Rossijskoe obshchestvo dermatovenerologov i kosmetologov. Moskva, 2015 g. 40 s. (In Russ).
3. Ha J, Lee SW, Yon DK. 10-year trends and prevalence of asthma, allergic rhinitis, and atopic dermatitis among the Korean population, 2008-2017. Clin Exp Pediatr. 2020 Jan 29. DOI: 10.3345/cep.2019.01291.
4. Price KN, Krase JM, Loh TY, et al. Racial and ethnic disparities in global Atopic Dermatitis clinical trials. Br J Dermatol. 2020 Feb 7. DOI: 10.1111/bjd.18938.
5. Aleksandrova G.A., Golubev N.A., Tyurina E.M. i dr. Zabolevaemost’ vzroslogo naseleniya Rossii v 2018 godu s diagnozom, ustanovlennym vpervye v zhizni. Statisticheskie materialy. CHast’ III. M.: Departament monitoringa, analiza i strategicheskogo razvitiya zdravoohraneniya Minzdrava Rossijskoj Federacii, FGBU «Central’nyj nauchno-issledovatel’skij institut organizacii i informatizacii zdravoohraneniya» Minzdrava Rossijskoj Federacii. 2019. (In Russ). http://mednet.ru/miac/meditsinskaya-statistika, обращение к ресурсу 12.12.2019.
6. Aleksandrova G.A., Golubev N.A., Tyurina E.M. i dr. Obshchaya zabolevaemost’ vzroslogo naseleniya Rossii v 2018 godu. Statisticheskie materialy. CHast’ IV. M.: Departament monitoringa, analiza i strategicheskogo razvitiya zdravoohraneniya Minzdrava Rossijskoj Federacii, FGBU «Central’nyj nauchno-issledovatel’skij institut organizacii i informatizacii zdravoohraneniya» Minzdrava Rossijskoj Federacii. 2019. (In Russ). http://mednet.ru/miac/meditsinskaya-statistika, обращение к ресурсу 12.12.2019.
7. Megna M, Patruno C, Balato A, et al. An Italian multicenter study on adult atopic dermatitis: persistent versus adult-onset disease. Arch Dermatol Res. 2017;309(6):443-452. DOI: 10.1007/s00403-017-1739-y.
8. Whiteley J, Emir B, Seitzman R, Makinson G. The burden of atopic dermatitis in US adults: results from the 2013 National Health and Wellness Survey. Curr Med Res Opin. 2016;32(10):1645-1651. DOI:10.1080/03007995.2016.1195733.
9. Sun D, Ong PY. Infectious complications in Atopic Dermatitis. Immunol Allergy Clin North Am. 2017;37(1):75-93. DOI: 10.1016/j.iac.2016.08.015.
10. Silverberg JI. Comorbidities and the impact of atopic dermatitis. Ann Allergy Asthma Immunol. 2019;123(2):144-151. DOI: 10.1016/j.anai.2019.04.020.
11. Paller A, Jaworski JC, Simpson EL, et al. Major comorbidities of Atopic Dermatitis: Beyond Allergic Disorders. Am J Clin Dermatol. 2018 Dec;19(6):821-838. DOI: 10.1007/s40257-018-0383-4.
12. Revyakina V.A., Taganov A.V., Kuvshinova E.D., et al. Atopic dermatitis, modern strategy in the therapy. Lechashchiy vrach. 2019;(5):32-37. (In Russ).
13. Gooderham MJ, Hong HC, Eshtiaghi P, Papp KA. Dupilumab: A review of its use in the treatment of atopic dermatitis. J Am Acad Dermatol. 2018;78(3 Suppl 1):S28-S36. DOI: 10.1016/j.jaad.2017.12.022.
14. Rasporyazhenie Pravitel’stva RF ot 12 oktyabrya 2019 g. № 2406-r. (In Russ). http://base.garant.ru/72861778/ обращение к ресурсу 28.10.2019.
15. Klinicheskie rekomendacii. (In Russ). http://spulmo.ru/upload/kr_bronhastma_2019.pdf; http://www.pediatr-russia.ru/sites/default/files/file/kr_bronhast2019.pdf), обращение к ресурсу 28.10.2019.
16. KSG «Lechenie s primeneniem genno-inzhenernyh biologicheskih preparatov i selektivnyh immunodepressantov» st36.003 i ds36.004 na 2020 god Instrukciya po gruppirovke sluchaev, v tom chisle pravila ucheta klassifikacionnyh kriteriev, i podhodam k oplate medicinskoj pomoshchi v ambulatornyh usloviyah po podushevomu normativu finansirovaniya. (In Russ). http://ffoms.ru/documents/the-orders-oms/, обращение к ресурсу 20.01.2020).
17. Farmakoepidemiologiya i farmakoekonomika praktika priemlemyh reshenij / Red. V.B. Gerasimov, A.L. Hohlov, O.I. Karpov. Moscow: Medicina, 2005. (In Russ).
18. Dupiksent® (dupilumab) ot 04.04.2019. Nomer LP-005440.] http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=3dc14deb-4a0f-4c66-bf915217c03b408a&t= (дата обращения 11.11.2019 г.).
19. Metodicheskie rekomendacii po raschetu zatrat pri provedenii kliniko-ekonomicheskih issledovanij lekarstvennyh preparatov. Utverzhdeny prikazom FGBU «CEKKMP» Minzdrava Rossii ot 29 dekabrya 2017 g. №185-od. (In Russ). https://rosmedex.ru/wp-content/uploads/2018/02/Metodicheskie-rekomendatsii-po-raschetu-zatrat-priprovedenii-kliniko-e%60konomicheskih-issledovaniy-lekarstvennyihpreparatov-2017.pdf (дата обращения 11.11.2019 г.).
20. Predel’nye razmery optovyh nadbavok i predel’nye razmery roznichnyh nadbavok k cenam na zhiznenno neobhodimye i vazhnejshie lekarstvennye preparaty, ustanovlennye v sub»ektah Rossijskoj Federacii. (In Russ). https://fas.gov.ru/documents/684978 (дата обращения 11.11.2019 г.).
21. Rossijskij farmacevticheskij portal «Farmindeks.rf». (In Russ). https://www.pharmindex.ru/ (дата обращения 05.11.2019 г.).
22. Ob utverzhdenii standarta pervichnoj mediko-sanitarnoj pomoshchi pri atopicheskom dermatite. Prikaz Minzdrava Rossii ot 09.11.2012 № 770n. (In Russ).
23. Gosudarstvennyj reestr lekarstvennyh sredstv. (In Russ). https://grls.rosminzdrav.ru/grls.aspx (дата обращения 11.11.2019 г.)
24. Postanovlenie Pravitel’stva RF ot 10 dekabrya 2018 goda №1506 «O programme gosudarstvennyh garantij besplatnogo okazaniya grazhdanam medicinskoj pomoshchi na 2019 god i na planovyj period 2020 i 2021 godov». (In Russ). http://government.ru/docs/35025/, обращение к ресурсу 01.11.2019.
25. Pis’mo Minzdrava Rossii ot 21.12.2018 N 11-7/10/1-511 «O formirovanii i ekonomicheskom obosnovanii territorial’noj programmy gosudarstvennyh garantij besplatnogo okazaniya grazhdanam medicinskoj pomoshchi na 2019 god i na planovyj period 2020 i 2021 godov». (In Russ). http://www.consultant.ru/document/cons_doc_LAW_314484/, обращение к ресурсу 01.11.2019.
26. Ob obyazatel’nom social’nom strahovanii na sluchaj vremennoj netrudosposobnosti i v svyazi s materinstvom. Federal’nyj zakon ot 29.12.2006 №255-FZ (In Russ). http://www.consultant.ru/document/cons_doc_LAW_64871/, обращение к ресурсу 01.11.2019.
27. Dannye Federal’noj sluzhby gosudarstvennoj statistiki. Srednemesyachnaya nominal’naya nachislennaya zarabotnaya plata rabotnikov v celom po ekonomike po sub»ektam Rossijskoj Federacii za 2000-2018 gg. (In Russ). https://www.gks.ru/labor_market_employment_salaries (дата обращения 11.11.2019 г.).
Review
For citations:
Krysanov I.S., Krysanova V.S., Karpov O.I., Ermakova V.Yu. Social-economic burden of severe atopic dermatitis in the Russian Federation. Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice. 2019;(4):4-14. (In Russ.)
Views:
758
Email this article 